Progressive saphenous vein graft (SVG) narrowing and occlusion remains a major limitation of coronary artery bypass grafting and is an important target for gene therapy. Ex vivo adenoviral gene transfer of tissue inhibitor of metalloproteinase 3 (TIMP-3) reduces adverse SVG remodelling postarterialization, but concerns remain over the use of viral vectors in patients. Ultrasound exposure (USE) in the presence of echocontrast microbubbles (ECM) substantially enhances nonviral gene delivery. We investigated the effects of ultrasound-enhanced gene delivery (UEGD) of TIMP-3 plasmid on vascular remodelling in porcine SVG. Maximal luciferase activity (3000-fold versus naked plasmid alone) and TIMP-3 transgene expression in porcine vascular smooth muscle cells in vitro was achieved using USE at 1 MHz, 1.8 mechanical index (MI), 6% duty cycle (DC) in the presence of 50% (v/v) BR14 ECM (Bracco). These conditions were therefore utilized for subsequent studies in vivo. Yorkshire White pigs received carotid interposition SVG that were untransfected or had undergone ex vivo UEGD of lacZ (control) ) controls (Po0.01). These data indicate that nonviral TIMP-3 plasmid delivery by USE achieves significant biological effects in a clinically relevant model of SV grafting, and is the first study to demonstrate the potential for therapeutic UEGD to prevent SVG failure.
Progressive saphenous vein graft (SVG) narrowing and occlusion remains a major limitation of coronary artery bypass grafting and is an important target for gene therapy. Ex vivo adenoviral gene transfer of tissue inhibitor of metalloproteinase 3 (TIMP-3) reduces adverse SVG remodelling postarterialization, but concerns remain over the use of viral vectors in patients. Ultrasound exposure (USE) in the presence of echocontrast microbubbles (ECM) substantially enhances nonviral gene delivery. We investigated the effects of ultrasound-enhanced gene delivery (UEGD) of TIMP-3 plasmid on vascular remodelling in porcine SVG. Maximal luciferase activity (3000-fold versus naked plasmid alone) and TIMP-3 transgene expression in porcine vascular smooth muscle cells in vitro was achieved using USE at 1 MHz, 1.8 mechanical index (MI), 6% duty cycle (DC) in the presence of 50% (v/v) BR14 ECM (Bracco). These conditions were therefore utilized for subsequent studies in vivo. Yorkshire White pigs received carotid interposition SVG that were untransfected or had undergone ex vivo UEGD of lacZ (control) or TIMP-3 plasmids. At 28 d postgrafting, lumen and total vessel area were significantly greater in the TIMP-3 group (10.171. 2 Progress in cardiovascular gene therapy has been hampered by concerns over the safety and practicality of viral vectors and the inefficiency of currently available nonviral transfection techniques. 1 We have previously demonstrated up to 10-fold enhancements in gene delivery to primary vascular smooth muscle cells (VSMC) and endothelial cells following ultrasound exposure (USE) in vitro, 2 increasing to up to 500-fold in the presence of echocontrast microbubbles (ECM). 3 The challenge for this technology remains the demonstration that it is 'sufficiently efficient' for therapeutic gene delivery in clinically relevant animal models of cardiovascular disease. Prevention of late saphenous vein graft (SVG) failure is an attractive and important target for therapeutic gene delivery and offers the opportunity for ex vivo manipulation of the vein prior to grafting into the coronary or peripheral circulation. 4, 5 It has previously been shown that ex vivo adenoviral gene transfer of tissue inhibitor of metalloproteinase 3 (TIMP-3) reduces adverse remodelling in porcine SVG. 6 Successful nonviral delivery of TIMP-3 is therefore highly appealing. The present study investigates whether ex vivo gene transfer of TIMP-3 plasmid using microbubble-enhanced ultrasound also influences arterialization-induced remodelling of porcine SVG.
The likely optimal ECM for in vivo studies was determined by comparing the effects of second-generation (Optisont) or third-generation (SonoVue s and BR14) ECM upon the efficiency of ultrasound-enhanced gene delivery (UEGD) in porcine VSMC in vitro. All these ECM contain perfluorocarbon gases rather than air (used in first-generation ECM) to improve circulating half-time in vivo, but Optisont is an albumin-based preparation, whereas SonoVue s and BR14 are phospholipid-stabilized microbubbles. 7, 8 Luciferase activity was extremely low in VSMC lysates following naked pGL3 luciferase plasmid transfection (0.470.05 Â 10 3 LU/mg protein) (Figure 1a ). Luciferase activity following USE was enhanced by all three ECM, reaching a maximum of 3000-fold over naked DNA alone using USE with 50% (v/v) BR14 (1.270.05 Â 10 6 LU/mg; Po0.001 versus DNA alone, Figure 1a ), significantly greater than using Optisont (maximum 0.4670.1 Â 10 6 LU/mg; Po0.05 versus BR14). BR14 was therefore used in combination with USE in all subsequent studies. The effect of ultrasound on TIMP-3 gene delivery was investigated by transfecting porcine VSMC with pCI-TIMP-3 using these USE parameters followed by Western blotting. Figure 1b (lane g) shows a dense TIMP-3 band that comigrated with recombinant human TIMP-3 when pCI-TIMP-3 was delivered using USE with 50% (v/v) BR14, whereas only low-level expression was detected in VSMC that were either untransfected, transfected with pCI-lacZ or pCI-TIMP-3 alone or underwent USE without plasmid.
The USE conditions defined above were then used to investigate the effect of ultrasound on gene delivery to intact SV. In a first series of experiments, segments of SV were transfected ex vivo with pGL3 luciferase plasmid (Figure 2a) , implanted into the carotid artery, harvested at 3 d and lysed for analysis of luciferase reporter gene expression by luminometry. All SVG were patent when harvested. Luciferase activity was 2.5-fold higher in SVG-transfected with pGL3 without USE compared to background readings in untransfected controls, but this difference was not statistically significant ( Figure 2b ). Luciferase activity was 20-fold higher than background in grafts undergoing ex vivo USE in the presence of 50% (v/v) BR14 (Figure 2b ). USE was associated with a greater than 50-fold enhancement in luciferase activity over naked DNA transfection alone when background readings are subtracted. These transfection conditions were therefore favourable in the context of intact vascular tissue and were utilized for the study of UEGD of pCI-TIMP-3 plasmid in SVG. For these experiments, untransfected SV or segments of SV-transfected ex vivo with pCI-TIMP-3 or a control plasmid (pCI-lacZ) were implanted into the carotid artery and harvested for histomorphometric analysis of SVG remodelling at 28 d. Of the 23 grafts harvested at 28 d, 19 (83%) were patent, 8/8 (100%) for vehicle alone, 6/8 (75%) for pCI-lacZ plasmid+USE and 5/7 (71%) for pCI-TIMP-3 plasmid+USE. Lumen area was significantly greater in the TIMP-3-transfected group compared to either untransfected or control plasmid (lacZ-transfected) controls (Figure 3a) . Total vessel area was also increased in the TIMP-3 group (Figure 3b ). Intima to media ratio (IMR) was significantly greater in the lacZ ultrasound Figure 1 Determining the optimal ECM for UEGD in porcine VSMC. Porcine VSMC (AG08477, Coriell Cell Repositories, Camden, NJ, USA) were cultured in DMEM containing 15% (v/v) fetal calf serum (TCS, Buckingham, UK). Transfections with the luciferase plasmid pGL3 (Promega, Southampton, UK) were performed in 24-well plates using a custom-built USE system (AFB) as described previously.
3 USE was performed at 1 MHz for 60 s at a mechanical index (MI) of 1.8, 6% duty cycle (DC), where applicable in the presence of varying concentrations (10-50% (v/v)) of the ECM SonoVue s or BR14 (4 Â 10 8 bubbles/ml stock, gifts from Bracco Research, Geneva) or Optisont (5 Â 10 8 bubbles/ml stock, Amersham Health, Bucks, UK). Luciferase activity in cell lysates was measured after 48 h as described previously 3 using an LB953 AutoLumat PLUS luminometer (Berthold Technologies UK Ltd, Redbourn, Herts, UK) and expressed as light units (LU)/mg total cell protein (BioRad protein assay kit, BioRad Laboratories, Munich, Germany). Data are presented as mean7standard error of the mean (s.e.m.). Data were normally distributed, so treatments were compared by ANOVA using Dunnett's test for post hoc comparisons and the Bonferroni correction was applied to account for multiple comparisons. Significance was defined as Po0.05. *Po0.05 versus naked DNA alone. (b) UEGD of TIMP-3 plasmid in porcine VSMC. Porcine VSMC were transfected with pCI-lacZ or pCI-TIMP-3 (pCI backbone from Promega) with or without USE as described above. TIMP-3 expression was assayed after 48 h in control and plasmidtransfected cultures by Western blotting 20 mg total cell protein using a mouse monoclonal anti-human TIMP-3 primary antibody that detects human and porcine TIMP-3 6 (1:500; TCS Cellworks Ltd, Buckingham, UK) with a goat anti-mouse IgG-horseradish peroxidase secondary antibody (1:1000; Dako, High Wycombe, UK). Lane a, recombinant human TIMP-3 (23 kDa, Sigma); b, untransfected VSMC; c, USE+BR14 (50% (v/v)); d, lacZ plasmid; e, lacZ plasmid+USE+BR14 (50% (v/v)); f, TIMP-3 plasmid; g, TIMP-3 plasmid+USE+BR14 (50% (v/v)). Figure 2 (a) Ex vivo UEGD to segments of porcine SV. SV was harvested from anaesthetized domestic crossbred Yorkshire White pigs (25-30 kg). Transfections were performed ex vivo by instilling 3 cm lengths of SV without distension with 200 ml culture medium containing 33 mg/ml pGL3, pCI-lacZ or pCI-TIMP-3 plasmids as appropriate (transfection medium, TM). The SV was suspended from a hollow steel needle in an ultrasound-lucent rubber balloon containing further TM and placed into a water bath within the extended focal zone of a custom-built 1 MHz ultrasound transducer (A.F.B.). Transfections were performed for a total of 60 min. Where applicable, the TM also contained 50% (v/v) BR14 and USE was performed for 60 s (1.8 MI, 6%DC) at the beginning and again at the end of the 60 min transfection period, replenishing the BR14-containing TM through the supporting needle after USE. (b) Ultrasound-enhanced luciferase reporter gene expression in porcine SV. Sixteen pigs received unilateral carotid interposition SVG as described previously for reporter gene studies. Grafts were randomly assigned to remain untransfected (control) or to undergo ex vivo transfection with pGL3 luciferase plasmid in the presence or absence of USE as described above prior to implantation. Grafts were harvested 3 d postimplantation, cut into 1 mm 3 cubes and incubated in Promega lysis buffer (E1531) on ice for 3 h before luminometry. Luciferase activity was expressed as LU per 5 mm graft length. Figure 3 Effect of ex vivo UEGD of TIMP-3 plasmid on SVG remodelling postarterialization. In all, 12 pigs received SVG (11 bilateral, one unilateral), with grafts randomly assigned to remain untransfected or to undergo ex vivo UEGD of pCI-lacZ or pCI-TIMP-3 plasmids using USE conditions described in the legend to Figure 2 . Grafts were harvested after 28 d, perfusion fixed with 10% (v/v) formalin in phosphate-buffered saline for 10 min at 100 mm Hg and paraffin embedded after 16 h in formalin. In all, 12 4-mm sections taken from the length of each fixed graft were stained with Miller's elastic van Giesen stain with Alcian Blue for semiautomated computerized morphometric analysis in an observer-blinded manner using a Nikon E600 light microscope attached to a Sony XC-711P video camera and Luciat software (Nikon). The mean for each parameter for each graft was calculated for statistical comparisons as described in the legend to Delivery of TIMP-3 plasmid DNA into saphenous vein EF Akowuah et al control group compared to untransfected grafts, whereas this was not seen in TIMP-3-transfected grafts ( Figure  3c ). There were no significant differences in media area between groups (5.471.2, 4.872.1 and 5.870.4 mm 2 in the untransfected, lacZ and TIMP-3 groups, respectively; P ¼ NS), whereas intimal area was greatest in the lacZ control group (1.970.1, 2.670.2 and 2.270.2 mm 2 in the untransfected, lacZ and TIMP-3 groups; Po0.001 versus untransfected). Representative histological sections from each of the treatment groups are shown in Figure 3 , panels d-f. These data indicate that UEGD of TIMP-3 induces positive remodelling in porcine SVG, with the beneficial effect of increased lumen size after 28 d.
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Our study shows that USE enhances nonviral gene delivery to primary VSMC in vitro by several orders of magnitude and demonstrates that UEGD to intact SV is 'sufficiently efficient' to achieve therapeutic effects in vivo. Although recent studies have demonstrated the efficacy of UEGD in small animal models of arterial injury and restenosis, these studies utilized highly artificial conditions requiring isolation of arterial segments and cessation of blood flow.
9,10 Our study shows for the first time that UEGD can also achieve potentially therapeutic effects in an animal model that closely mimics the clinical procedure of SV grafting. Specifically, we have demonstrated that ex vivo UEGD of TIMP-3 plasmid is associated with increased lumen and total vessel size at 28 d compared with both untransfected SVG and controls receiving identical USE with the lacZ plasmid. Part of the success of this approach likely reflects the choice of therapeutic transgene. It has been reported that transient overexpression of TIMP-3 using an adenoviral vector reduces adverse SVG remodelling, focusing upon effects on intimal thickness, whereas our study showed particularly striking effects upon lumen and total vessel areas. 6 TIMP-3 is particularly suited to SVG gene therapy as it is a secreted protein that binds extracellular matrix (and is thereby maintained locally) and exhibits a prolonged bystander effect to induce apoptosis of surrounding VSMC. 6 These properties make TIMP-3 a particularly attractive gene for nonviral approaches that are generally less efficient than viral vectors. It has recently been confirmed that inducing VSMC apoptosis immediately after arterialization has beneficial effects on SVG remodelling measured later at 28 d, as adenoviral overexpression of another proapoptotic gene, p53, also increased lumen size in arterialized SVG, and these phenotypic changes were sustained well beyond the duration of exogenous transgene expression. 11 Although the results of this first study of UEGD in SVG are encouraging, our data clearly identify significant issues that need to be addressed in future. In particular, the higher IMR in the lacZ control group compared to untransfected SVG suggests that the ultrasound parameters employed may have caused some damage prior to implantation that promoted subsequent neointima formation, although there were no differences in endothelial coverage between groups or evidence of inflammation at 28 d (data not shown). While all transfection techniques are associated with some degree of toxicity, future studies will concentrate upon identifying and minimizing early toxicity while maintaining or improving biological efficacy. As well as altering the fundamental USE parameters, an additional possibility would be to perform ex vivo UEGD in the presence of N-acetyl cysteine, since we have previously shown that free radicals produced in response to USE are not required for UEGD and are potentially toxic to SVG. [12] [13] [14] Of particular importance in assessing potential therapeutic utility will be studies to define the effects of UEGD upon SVG at later time points. Notwithstanding these issues, we believe that the results of the present study, along with the relative simplicity, acceptability and practicality of UEGD, indicate that further optimization and development of ex vivo ultrasound gene therapy towards clinical use to prevent SVG failure is warranted. Moreover, advances in microbubble engineering to produce targeted and plasmid-bearing microbubbles also offers the opportunity for repeated UEGD of therapeutic transgenes to SVG and other cardiovascular target tissues in situ. 8, 15, 16 
